哌拉西林/三唑巴坦与头孢哌酮/舒巴坦治疗呼吸道细菌感染的成本-效果分析

目的评价哌拉西林/三唑巴坦与头孢哌酮/舒巴坦治疗呼吸道细菌感染的成本-效果。方法参考有关文献,对分别采用哌拉西林/三唑巴坦(试验组)与头孢哌酮/舒巴坦(对照组)治疗80例呼吸道中、重度细菌感染者的效果进行药物经济学成本-效果分析。结果对照组、试验组成本分别为211.80、165.60元;有效率分别为92.5%、90%(P>0.05);成本-效果比分别为2.29、1.84;对照组相对于试验组的增量成本-效果比为18.48。结论哌拉西林/三唑巴坦治疗呼吸道细菌感染相对于头孢哌酮/舒巴坦具有明显的药物经济学优势。

Cost-effectiveness Analysis on Piperacillin/Tazobactam and Cefoperazone/Sulbactam in the Treatment of Bacterial Infection of Respiratory Tracts

OBJECTIVE: To evaluate the cost-effectiveness of piperacillin/tazobactam and cefoperazone/sulbactam for bacterial infection of respiratory tracts. METHODS: Referenced by the related literature, the cost-effectiveness of the regimes of piperacillin/tazobactam(trial group) and cefoperazone/sulbactam(control group) in treating 80 patients with moderate or severe bacterial infections were evaluated. RESULTS: The costs of the control group and the trial group were 211.80 yuan and 165.60 yuan, respectively; The effective rates were 92.5% and 90%, respectively(P>0.05);The cost-effectiveness ratios were 2.29 and 1.84, respectively;The incremental cost-effectiveness ratio of the control group as against the trial group was 18.48. CONCLUSION: The therapy of piperacillin/tazobactam has marked pharmacoeconomics advantage over cefoperazone/sulbactam in treating bacterial infection of respiratory tracts.